FindTrial
Sign In

Expanded Access to ANG1005 for Individual Patients

Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Astrocytoma; Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Oligodendroglioma; Expanded Access to ANG1005 for an Individual Breast Cancer Patient With Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT02755987
Enrollment
Unknown
Registered
2016-04-29
Start date
Unknown
Completion date
Unknown
Last updated
2016-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis

Brief summary

This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1005-CLN-04 with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.

Interventions

DRUGANG1005

Sponsors

Angiochem Inc
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum

Inclusion criteria

1. Neurologically stable 2. Karnofsky performance status (KPS) ≥ 80 3. Adequate laboratory results

Exclusion criteria

1. Radiotherapy within 3 months. 2. Evidence of significant intracranial hemorrhage 3. NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 Grade ≥ 2 neuropathy 4. Inadequate bone marrow reserve 5. Any evidence of severe or uncontrolled disease

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026